By Sabela Ojea


Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's drug.

Earlier this month, the Food and Drug Administration gave early approval to the treatment, Lecanemab.

The drug should be delivered to patients diagnosed with a mild cognitive impairment or a mild dementia stage of disease, Biogen said.

The biotechnology company developed the treatment with Tokyo-based Eisai Co., Ltd.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

01-26-23 1911ET